Nephron [creativecommons license] via Wikimedia CommonsOvarian clear-cell carcinoma (OCCC) is an aggressive form of cancer. Although its incidence is not high, accounting for 5–20% of all epithelial ovarian cancers (EOCs), it has a poorer prognosis, higher recurrence and lower survival than other EOC types, particularly when diagnosed at advanced stages. A better understanding of OCCC development and progression could lead to improved treatments and outcomes for those affected, and a new tool for studying OCCC holds promise for delivering this necessary insight. Scientists at University of North Carolina (Chapel Hill) recently announced the creation of a genetically engineered mouse model of OCCC that recapitulates the disease in humans. The model could be used to test potential therapies and to identify disease markers for diagnostic screening.